Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epaminurad and C2406 DDI Study in Healthy Adults
NCT06665425Phase 1Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Mar 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of epaminurad and C2406 in gout, sponsored by JW Pharmaceutical Corporation. Primary endpoints: Area under the plasma concentration versus time curve at 7 days and Peak plasma concentrations at 7 days. Started Mar 2025; status: completed.
02
Drugs
epaminuradC2406
03
Conditions
gout
Beyond the preview
Go deeper on NCT06665425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06665425.